Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Trial Details

NCT ID
NCT06134232
Phase
PHASE2
Sponsor
Dendreon
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Sipuleucel-T Injection
Locations (sample)
  • Tuscon, Arizona, United States
  • Duarte, California, United States|34.13945,-117.97729
  • Fresno, California, United States|36.74773,-119.77237
  • San Diego, California, United States|32.71571,-117.16472
  • Lakewood, Colorado, United States|39.70471,-105.08137

Key Eligibility Criteria

  • For a subject to be eligible for participation in this study, all of the following criteria must be satisfied:
  • Potential subjects are men aged ≥18 years who are clinically indicated for treatment with PROVENGE® (asymptomatic or minimally symptomatic metastat…
  • Have qualified for on-label PROVENGE® infusion
  • Have received all 3 infusions of PROVENGE® prior to randomization

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →